Singapore markets closed

DBS CEO says tough for digital banks to muscle into Singapore

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.62-1.47 (-7.70%)
At close: 04:00PM EST
17.62 0.00 (0.00%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close19.09
Bid17.21 x 2900
Ask17.62 x 1800
Day's range17.39 - 19.10
52-week range12.90 - 39.12
Avg. volume1,899,817
Market cap2.511B
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-1.88
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est35.19
  • Motley Fool

    Cathie Wood's Buying Beam Therapeutics -- Should You?

    Over the past year, shares of Beam Therapeutics (NASDAQ: BEAM) have soared over 174% higher. This is the firm founded and still run by Cathie Wood, one of the world's most famous investors. Beam Therapeutics is pioneering the use of a new base editing technique in the development of new gene therapies.

  • Zacks

    Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

    Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

  • Motley Fool

    Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript

    Hello, thank you for standing by, and welcome to Allogene Therapeutics Third Quarter 2021 Conference Call. After the market closed today, Allogene issued a press release that provides a corporate update and financial results for Q3 2021. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.